Catawba Capital Management’s AbbVie ABBV Stock Holding History

Catawba Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$2.93M	Buy	31,624 +420	+1%	+$41K	0.69%	52
2018 Q1	$2.95M	Hold	31,204	–	–	0.71%	51
2017 Q4	$3.02M	Sell	31,204 -9,799	-24%	-$924K	0.68%	52
2017 Q3	$3.64M	Sell	41,003 -33	-0.1%	-$2.51K	0.82%	45
2017 Q2	$2.98M	Buy	41,036 +1,335	+3%	+$89.7K	0.68%	54
2017 Q1	$2.59M	Sell	39,701 -860	-2%	-$54.1K	0.56%	61
2016 Q4	$2.54M	Sell	40,561 -16	-0%	-$977	0.59%	59
2016 Q3	$2.56M	Buy	40,577 +535	+1%	+$34.6K	0.61%	55
2016 Q2	$2.48M	Sell	40,042 -100	-0.2%	-$6.09K	0.6%	57
2016 Q1	$2.29M	Buy	40,142 +55	+0.1%	+$3.07K	0.58%	57
2015 Q4	$2.38M	Sell	40,087 -615	-2%	-$35.4K	0.65%	55
2015 Q3	$2.21M	Sell	40,702 -1,570	-4%	-$102K	0.61%	56
2015 Q2	$2.84M	Buy	42,272 +675	+2%	+$44.1K	0.68%	51
2015 Q1	$2.44M	Hold	41,597	–	–	0.56%	59
2014 Q4	$2.72M	Buy	41,597 +733	+2%	+$46.2K	0.63%	54
2014 Q3	$2.36M	Sell	40,864 -920	-2%	-$51.1K	0.55%	67
2014 Q2	$2.36M	Sell	41,784 -170	-0.4%	-$8.92K	0.53%	68
2014 Q1	$2.16M	Sell	41,954 -2,245	-5%	-$113K	0.51%	68
2013 Q4	$2.33M	Sell	44,199 -1,104	-2%	-$54.3K	0.56%	66
2013 Q3	$2.03M	Buy	45,303 +105	+0.2%	+$4.65K	0.53%	68
2013 Q2	$1.87M	Buy	+45,198	New	+$1.98M	0.52%	70

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Catawba Capital Management's ABBV Position: Q2 2018 in Review

Catawba Capital Management increased its AbbVie (ABBV) stake by 1.3% in Q2 2018, buying an estimated $41K and bringing the position to 31,624 shares worth $2.93M. The position accounts for 0.69% of the portfolio, ranked #52.

Catawba Capital Management first reported a position in ABBV in Q2 2013 and has held it in 21 quarters since. The position peaked at $3.64M in Q3 2017. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Catawba Capital Management held 31,624 shares of AbbVie worth $2.93M as of Q2 2018.
Catawba Capital Management bought 420 AbbVie shares in Q2 2018, an estimated $41K.
AbbVie made up 0.69% of Catawba Capital Management's portfolio in Q2 2018, its #52 holding.
Catawba Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 21 quarters since.
Catawba Capital Management's AbbVie position peaked at $3.64M in Q3 2017.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.